Any current/future capex/capital investment/strategic investment?

Biosimilars investment to date: approximately $450 million (CapEx + OpEx) since July 2018. New greenfield biological CMO facility (Unit-2) investment: around $175 million. CDMO Unit-1 (60 KL capacity) commissioning expected by end of 2026; revenues to start in 2028. CDMO Unit-2 commissioning expected in 2029; revenues from 2031. Backward integration initiatives in Pen-G and 6-APA to strengthen supply security and improve margins. Ongoing geographic expansion supported by focused launches, portfolio expansion, and selective acquisitions. Continued investment in China OSD facility to scale appro

Future growth expectations in sales/revenue/volumes?

U.S. business targets $2 billion revenue milestone in near term, driven by acquisitions (Lannett ~$300 million) and new product launches; base US business expected to grow through in-licensing and ANDA acquisitions. Europe formulations achieved €1 billion annual revenue in FY26; expected to sustain minimum double-digit growth in constant currency, supported by new launches and increased supply from China. Biosimilars business aiming for 7-8 products commercialized in Europe and growth markets, plus 2-3 products in the US by 2030, expecting a significant inflection point. Specialty Inject

Future growth expectations in earnings/operating earnings/profits/EPS?

FY27 EBITDA margin guidance is expected to sustain and progressively improve to north of 21%, factoring in scale, execution capabilities, and new business levers. EBITDA is projected to benefit by around ₹100 crores for every 1% depreciation in INR against USD, though rising raw material and freight costs may offset benefits. Pen-G and 6-APA segments achieved positive EBITDA contribution recently with improvements expected to continue. China plant expects to move from EBITDA loss to profitable contribution in FY27. U.S. business targets $2 billion revenue in near term, driven by base b

IN US

Sale is live|00:00:00left today

Aurobindo Pharma LtdQ1 FY26Pharmaceuticals & Biotechnology

Aurobindo Pharma Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,555P/E: 24.9Market Cap: ₹87.8K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→U.S. business targets $2 billion revenue milestone in near term, driven by acquisitions (Lannett ~$300 million) and new product launches; base US business expected to grow through in-licensing and ANDA acquisitions.
→Europe formulations achieved €1 billion annual revenue in FY26; expected to sustain minimum double-digit growth in constant currency, supported by new launches and increased supply from China.
→Biosimilars business aiming for 7-8 products commercialized in Europe and growth markets, plus 2-3 products in the US by 2030, expecting a significant inflection point.
→Specialty Injectable segment excluding Revlimid expects double-digit growth going forward.
→Biological CDMO Unit-1 revenues to commence in 2028, Unit-2 from 2031, aiming to become a multi-customer CDMO by 2032.
→Overall FY27 outlook anticipates calibrated profitable growth with EBITDA margins north of 21%, supported by strong portfolio and operational excellence.

Margin guidance

Category 3

→FY27 EBITDA margin guidance is expected to sustain and progressively improve to north of 21%, factoring in scale, execution capabilities, and new business levers.
→EBITDA is projected to benefit by around ₹100 crores for every 1% depreciation in INR against USD, though rising raw material and freight costs may offset benefits.
→Pen-G and 6-APA segments achieved positive EBITDA contribution recently with improvements expected to continue.
→China plant expects to move from EBITDA loss to profitable contribution in FY27.
→U.S. business targets $2 billion revenue in near term, driven by base business growth, acquisitions (e.g., Lannett), and in-licensing; EBITDA expected to improve accordingly.
→European business growth is expected to continue at a minimum double-digit rate in constant currency, contributing to profitability.
→Biosimilars projected to achieve steady margin improvements and commercial traction by 2030, with 7-8 products in Europe and growth markets and 2-3 in the U.S.
→Overall outlook emphasizes calibrated and profitable growth, improved revenue visibility, and stronger cash flow generation.

3 more insights locked — sign up free to unlock

Fundraise plans

The transcript on page 23 and surrounding pages does not mention any current or future fundraising plans through debt or equity for Aurobindo Pharma Limited. Key points include: - No explicit discussion or guidance on raising new funds via debt or equity during the Q&A. - Focus is on organic growth, acquisitions (like Lannett acquisition), and scaling operations. - Emphasis on disciplined execution, capital allocation, and sustainable value creation without indicating new fundraising. - Financial outlook highlights EBITDA margin improvements and revenue growth visibility but no fundraising details. Therefore, based on the provided transcript, there is no indication of plans for new fundraising through debt or equity at this time.

Order book

Yes

The transcript across the document does not explicitly mention the current or expected order book or pending orders for Aurobindo Pharma Limited. However, some relevant insights can be inferred: - The company is working on multiple key launches and partnerships, including biosimilars and biologics, which suggest a robust pipeline. - Biosimilar US filings and European approvals are expected in 2026-2030, indicating a growing order stream for these products. - The CDMO units (Unit-1 and Unit-2) anticipate revenues starting from 2028 and 2031 respectively, implying pending contract manufacturing orders. - The Pen-G plant has started external sales with over ₹100 crores worth sales last quarter, indicating existing orders. - The integration of Lannett and ongoing business development initiatives hint at potential order inflows supporting the $2 billion US revenue target. - No specific quantification of order book or pending orders is provided in the transcript.

Capex plans

Yes

→Biosimilars investment to date: approximately $450 million (CapEx + OpEx) since July 2018.
→New greenfield biological CMO facility (Unit-2) investment: around $175 million.
→CDMO Unit-1 (60 KL capacity) commissioning expected by end of 2026; revenues to start in 2028.
→CDMO Unit-2 commissioning expected in 2029; revenues from 2031.
→Backward integration initiatives in Pen-G and 6-APA to strengthen supply security and improve margins.
→Ongoing geographic expansion supported by focused launches, portfolio expansion, and selective acquisitions.
→Continued investment in China OSD facility to scale approvals and supplies, especially for Europe.
→Emphasis on disciplined execution and prudent capital allocation for sustainable long-term value creation.

How does Aurobindo Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Aurobindo Pharma Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Aurobindo Pharma Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio